Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Express News | AtriCure Receives Expanded Indication For AtriClip In Europe For High-Risk Thromboembolism Patients, Validating Its Effectiveness In Reducing Stroke Events During Cardiac Surgery
Express News | AtriCure Receives Expanded Ce-Mark Indication for Atriclip® Devices for the Reduction of Stroke in Patients With Atrial Fibrillation
AtriCure Receives Expanded CE-Mark Indication for AtriClip Devices for the Reduction of Stroke in Patients With Atrial Fibrillation
CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $49
Atricure's Market Strength and Innovation Justify Buy Rating
US$39.89: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest Results
US$40.89: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest Results
AtriCure Second Quarter 2024 Earnings: EPS Misses Expectations
Oppenheimer Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $32
Navigating 6 Analyst Ratings For AtriCure
AtriCure Price Target Cut to $53.00/Share From $58.00 by BTIG
AtriCure Is Maintained at Buy by BTIG
Express News | JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30
AtriCure | 10-Q: Q2 2024 Earnings Report
A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $26 to $60
Express News | Needham Maintains Buy on AtriCure, Lowers Price Target to $34
AtriCure Price Target Cut to $40.00/Share From $65.00 by Piper Sandler
AtriCure Is Maintained at Overweight by Piper Sandler
AtriCure Analyst Ratings